

The Level of Inflammatory Tear Cytokines is Elevated in Congenital Aniridia and Associated with Meibomian Gland Dysfunction

Erlend C. S. Landsend,^{1,2} Øygunn A. Utheim,^{1,3} Hilde R. Pedersen,⁴ Hans Christian D. Aass,³ Neil Lagali,⁵ Darlene A. Dartt,⁶ Rigmor C. Baraas,⁴ and Tor P. Utheim^{1,3,7-10}

¹Department of Ophthalmology, Oslo University Hospital, Oslo, Norway

²Faculty of Medicine, University of Oslo, Oslo, Norway

³Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway

⁴National Centre for Optics, Vision and Eye Care, Faculty of Health and Social Sciences, University College of Southeast Norway, Kongsberg, Norway

⁵Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

⁶Schepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States

⁷Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway

⁸Department of Maxillofacial Surgery, Oslo University Hospital, Oslo, Norway

⁹Department of Ophthalmology, Stavanger University Hospital, Stavanger, Norway

¹⁰Department of Clinical Medicine, Faculty of Medicine, University of Bergen, Bergen, Norway

Correspondence: Erlend C. S. Landsend, Department of Ophthalmology, Oslo University Hospital, Mailbox 4950 Nydalen, 0424 Oslo, Norway; elandsend@gmail.com.

Submitted: February 4, 2018

Accepted: March 31, 2018

Citation: Landsend ECS, Utheim ØA, Pedersen HR, et al. The level of inflammatory tear cytokines is elevated in congenital aniridia and associated with meibomian gland dysfunction. *Invest Ophthalmol Vis Sci*. 2018;59:2197-2204. <https://doi.org/10.1167/iovs.18-24027>

PURPOSE. To investigate the tear cytokine profile in congenital aniridia, and correlate cytokine levels with ophthalmologic findings.

METHODS. We examined 35 patients with aniridia and 21 healthy controls. Tear fluid was collected with Schirmer I test and capillary tubes from each eye, and the concentration of 27 inflammatory cytokines determined using multiplex bead assay. Eyes of all participants were examined with tests for dry eye disease, including evaluation of meibomian glands (meibography). Differences in cytokine levels between the two groups were analyzed, and correlations between cytokine concentrations and ophthalmologic findings in the aniridia group investigated.

RESULTS. The concentrations of six tear cytokines were significantly higher in aniridia patients than controls in both eyes, and included interleukin 1 β (IL-1 β), IL-9, IL-17A; eotaxin; basic fibroblast growth factor (bFGF/FGF2); and macrophage inflammatory protein 1 α (MIP-1 α /CCL3). The ratio between the anti-inflammatory IL-1RA and the proinflammatory IL-1 β was significantly lower in patients than controls in both eyes ($P = 0.005$ right eye and $P = 0.001$ left eye). Increasing concentration of IL-1 β , IL-9, IL-17A, FGF2, and MIP-1 α correlated with parameters for meibomian gland dysfunction (MGD) in the aniridia group, including increasing atrophy of meibomian glands, and shorter break-up time of the tear film.

CONCLUSIONS. A number of pro-inflammatory cytokines are significantly elevated in tear fluid from aniridia patients, and correlate with parameters for MGD in aniridia. Increased inflammation of the ocular surface may be a factor in the development of MGD in aniridia patients, and explain the high prevalence of MGD and dry eye disease in these patients.

Keywords: inflammation, cytokine, tear film, aniridia, dry eye

Congenital aniridia is a rare disorder that affects both anterior and posterior parts of the eye, including the cornea, iridocorneal angle, iris, lens, retina, and optic nerve. The prevalence in Norway is 1:76,000.¹ Hypoplasia of the iris and of macula lutea is present in most patients and commonly results in photophobia, considerably reduced visual acuity, and nystagmus. Progressive ocular disorders such as glaucoma, cataract, and aniridia-associated keratopathy (AAK) are common.^{1,2} Mutation in the *PAX6* gene is the major genetic explanation for aniridia.³

The prevalence of dry eye disease (DED) in aniridia is high.⁴ Besides, significant correlation has been found between DED

and the severity of AAK.⁵ As AAK is a sight-threatening complication, investigations of DED in aniridia patients may provide important knowledge that brings better visual outcome.

Increased levels of various inflammatory cytokines in the tear fluid have been demonstrated in DED.⁶ Moreover, elevated concentration of these cytokines was correlated with increased severity of DED. Inflammation can lead to ocular surface epithelial disease and altered corneal epithelial barrier function in DED.⁷ DED may thus initiate AAK through activating inflammatory pathways. In turn, AAK might exacerbate DED through inducing inflammatory cascades, creating a vicious



circle. To our knowledge, this is the first published study to comprehensively analyze inflammatory tear cytokines in aniridia patients. By investigating the tear cytokine profile in these patients, we aim to add clues to the pathogenesis of DED in aniridia, which may pave the way for improved treatment of ocular surface pathology.

METHODS

Study Subjects

The study comprised 35 patients (21 females) with congenital aniridia (age range: 9–72 years) and 21 healthy controls (12 females; age range: 19–65 years). The aniridia group was recruited through the patient organization Aniridia Norway. Patients had previously been diagnosed with aniridia, and the diagnosis was confirmed by ophthalmoscopy before inclusion in the study. Ethics committee approval was obtained from the Norwegian Regional Committees for Medical and Health Research Ethics (Application no. 2014/382) and the study was conducted in accordance with the tenets of the Declaration of Helsinki. All participants gave written consent after receiving oral and written information about the study.

Dry Eye Examination, Sample Collection and Storage

Results from dry eye examinations were used for correlation analysis with cytokine concentrations. The results from dry eye examinations were presented in a separate manuscript.

Measurement of Tear Production and Collection of Tear Fluid

Tear meniscus height was measured with a corneal topographer (OCULUS Keratograph 5M; OCULUS, Wetzlar, Germany). Tear fluid was collected with Schirmer I tear test using test strips (Schirmer Tear Test Strips; Haag-Streit UK, Essex, UK), and capillary tubes. Collection was performed without topical anesthesia. Wearing gloves, the examiner placed the test strip (Haag-Streit UK) at the lateral eyelid margin. The participants had their eyes closed during the procedure, and both eyes were tested simultaneously. The strip was removed after 5 minutes, and the wetted part measured on a millimeter scale up to the indentation line. The strip was then stored in a cuvette containing 500 mL phosphate buffered saline, which was subsequently placed in a deep freezer at -80°C .

Tear production was further measured with a phenol red thread test (Tianjin JingMing New Technological Development Co., Tianjin, China), without topical anesthesia and for 15 seconds.

Next, tear fluid was collected in capillary tubes. To obtain contact with the tear meniscus, the tube end was placed at the lateral lower eyelid margin, avoiding contact with the eyelid or bulbar conjunctiva. Samples were collected from both eyes, and the capillary tubes stored at -80°C .

Measurement of Tear Film Quality and Ocular Surface Staining

Tear film osmolarity was measured with commercial equipment (TearLab; TearLab Corp., San Diego, CA, USA). Tear film lipid layer was evaluated by recording interference images on the keratograph during several blink intervals (lipography). The test was designated as positive if spread of the lipid layer could be observed, or negative if not.

Fluorescein break-up time was measured after placing 5 μL of 2% fluorescein sodium (Minims Fluorescein Sodium 2%; Bausch & Lomb House, Surrey, UK) into the conjunctival sac. The time from a blink to break up of the tear film was then measured. Without delay, punctate fluorescein vital staining of the conjunctiva and cornea was then assessed using the Oxford grading scheme.⁸

Corneal Sensitivity

Central corneal sensitivity was measured using an esthesiometer (Cochet-Bonnet; Luneau Ophthalmology, Chartres, France). The esthesiometer contained a 60-mm long monofilament, which was retracted in 5-mm steps from its full length, until a blink response was elicited.

Examination of Eyelids

Eyelid pathology was denoted as either present or absent in each of the following eight groups: debris at the eyelid margin, edema and thickening of the eyelid, irregularity of the lid margin, hyperemia in the eyelid, telangiectasia in the eyelid, occlusion of gland orifices at the lid margin, and presence of conjunctival papillae or conjunctival hyperemia.

Expression of meibomian glands (MGs) was performed in lower eyelid, and expressibility based on number of central five glands that expressed secretion. Quality of expressed secretion was graded according to recommendations from the International Workshop on meibomian gland dysfunction.⁹

MGs were visualized taking infrared images with the keratograph. MG loss in upper and lower eyelid was evaluated subjectively and staged according to a four-point scale (meiboscore). The percentage area of MG loss was defined as the area of MG loss in relation to the total visible tarsal area and given a score from 0 to 3. A score of 0 represented an area of MG loss of 0% to 25%; a score of 1 represented an area of MG loss of 26% to 50%; a score of 2 represented an area of MG loss of 51% to 75%; and score of 3 represented an area of MG loss of $>75\%$.

Clinical Evaluation of the Eye

Anterior part of the eye was examined with a slit-lamp biomicroscope. AAK was graded according to a modification of Mackman's classification.¹⁰ Stage 0 indicated no involvement of the cornea; stage 1 referred to ingrowth of conjunctival tissue in the peripheral cornea from less than 360° of the corneal limbus; stage 2 related to 360° conjunctivalization of the peripheral cornea, but clear central cornea; and stage 3 described presentation as in stage 2, but included conjunctival vascularization and/or stromal involvement of the central cornea. Amount of iris hypoplasia was classified as either total, if no iris tissue was visible, or partial if some tissue could be seen. Stage of cataract was graded according to the Lens Opacities Classification System III.¹¹

Analyses of Tear Fluid

Cytokine concentration in the tear fluid was measured using immunoassay technology (Bio-Plex XMap; Bio-Rad Laboratories, Inc., Hercules, CA, USA) with a commercial instrument (Luminex IS 100; Luminex Corp., Austin, TX, USA) powered by commercial software (Bio-Plex version 6.0.1; Bio-Rad Laboratories, Inc.). Do modest sample volumes, the multiplex assay was performed with half the standard sample volume, beads, detection antibody, and streptavidin-phycoerythrin. To optimize the assay for low-level detection, screening was carried out with an additional standard point along with increased

TABLE 1. Number of Tear Samples and Corresponding Age in Each Test Group

Test	Aniridia, <i>n</i>	Control, <i>n</i>	Aniridia, Age, y ^a	Control, Age, y ^a
Schirmer OD	27	19	36.2	29.4
Schirmer OS	26	17	35.7	29.2
Capillary OD	22	18	37.9	30.4
Capillary OS	19	13	36.3	32.2

* Mean.

incubation time of beads and sample up to an hour. The broad screening kit (Bio-Plex Pro Human Cytokine 27-plex Assay, Cat. No. M50-0KCAF0Y; Bio-Rad Laboratories, Inc.) contained 27 different cytokines: IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-1RA (receptor antagonist); eotaxin, basic fibroblast growth factor (bFGF/FGF2); granulocyte colony-stimulating factor; granulocyte macrophage colony-stimulating factor; interferon gamma; interferon gamma-induced protein 10; monocyte chemoattractant protein 1; macrophage inflammatory protein 1 β (MIP-1 α /CCL3); MIP-1 β ; platelet-derived growth factor bb; regulated-on-activation normal T cell expressed and secreted; tumor necrosis factor alpha; and vascular endothelial growth factor.

Not all participants completed the Schirmer and capillary test, and from some of them no visible tear fluid was collected in the capillary tubes. To ensure sufficient tear fluid for analyses, 11 Schirmer tests with 5-mm wetting or less were discarded (five from aniridia group and six from control group). All tear samples were thawed on ice and 6 μ L of tear fluid from capillary tubes were mixed with 24 μ L of sample diluent and added to the test plate. In a small number of cases in which tear fluid volume was less than 6 μ L, sample diluent was added to final volume of 30 μ L, and the diluent factor adjusted accordingly. The cuvettes with Schirmer strips stored in phosphate buffered saline were vortexed, and 25 μ L of the suspension was added directly to the plate. Individual sets of samples from patients were run on the same plate. Plates were washed with a magnetic plate washer (Bio-Plex Pro Wash Station; Bio-Rad Laboratories, Inc.). The standard curve for each cytokine was performed in duplicate using recombinant proteins in a 4-fold dilution. Results were validated by a five-parametric logistic curve modeling and used to determine the protein levels in the tear fluid samples. Longitudinal controls were applied to obtain inter- and intrapercent coefficient of variation. All values were in acceptable range according to recommendations from the manufacturer (intrapercet coefficient of variation <11 and interpercent coefficient of variation >21). Protein concentrations in the Schirmer strip suspensions were adjusted as a direct function of the total length of wetted strip, which was calculated from the Schirmer test result.

Quantitative and Statistical Analyses

Statistical analyses were performed with statistical software (SPSS software version 23.0; IBM Corp., Armonk, NY, USA). Cytokine levels were calculated in four groups: Schirmer test right eye (SOD) and left eye (SOS), and capillary test right eye (COD) and left eye (COS). Reported results are presented as means \pm standard deviation. Normal distribution was analyzed using Shapiro-Wilk test and histogram analysis, and Mann-Whitney *U* test applied to calculate differences in cytokine levels between aniridia and control subjects. The alpha level was set to 0.05 and significant results determined by the Holm-Bonferroni method to correct for multiple comparisons. Correlation analyses between cytokine levels and clinical

TABLE 2. Tear Cytokines in Right Eye With Significantly Different Concentrations in Aniridia and Control Group

Cytokine	Aniridia	Control	<i>P</i> Value ^a
IL-1 β Schirmer test (S)	10.3 \pm 17.2	1.8 \pm 5.4	0.0001
IL-1 β capillary test (C)	13.3 \pm 8.7	4.3 \pm 3.3	0.00003
IL-2 (C)	15.9 \pm 13.7	4.1 \pm 5.9	0.002
IL-9 (S)	6.5 \pm 5.0	2.3 \pm 3.8	0.001
IL-9 (C)	35.3 \pm 19.3	16.8 \pm 12.7	0.001
IL-17A (S)	20.7 \pm 27.0	5.5 \pm 21.1	0.0004
IL-17A (C)	105.8 \pm 111.9	2.4 \pm 10.2	0.00003
Eotaxin (C)	88.9 \pm 47.7	52.5 \pm 27.2	0.002
FGF2 (S)	65 \pm 54.4	19.4 \pm 74.5	0.0002
FGF2 (C)	189.3 \pm 150.6	10.3 \pm 43.9	0.00003
MIP-1 α (S)	1.8 \pm 1.4	0.7 \pm 1.7	0.001
MIP-1 α (C)	13.0 \pm 6.4	7.1 \pm 4.7	0.001

Mean \pm SD; cytokines (pg/mL).^a Mann-Whitney *U* test and Holm-Bonferroni method.

parameters in the aniridia group were performed using Spearman's rank correlation and values of $P \leq 0.05$ considered as significant.

RESULTS

Mean age in the aniridia group was 34.9 \pm 18.7 (range: 9–72) years and 31.2 \pm 13.9 (range: 19–65) years in the control group. Table 1 shows number of tests and mean age of participants in the four subgroups combining Schirmer/capillary test and right/left eye. In aniridia patients, mean Schirmer test result was 27.5 \pm 9.4 mm in right eye and 27.7 \pm 9.1 mm in left eye.

Comparison of Cytokine Levels Between Aniridia and Control Groups

In the SOD group, the concentrations of five cytokines were significantly higher in aniridia patients than control subjects; in the COD group, the levels of six cytokines were significantly elevated in aniridia group (Table 2); in the SOS group, 17 cytokines had increased concentration in aniridia subjects; and in the COS group, the levels of two cytokines were higher in aniridia than controls (Table 3). None of the cytokines tested had significantly lower concentrations in the aniridia group than in the control group.

The concentrations were significantly higher for seven cytokines in the right eye and 17 in the left eye in either one or both test modalities. Consequently, a lower number of tear cytokines had increased concentrations in the right versus the left eye, but all the cytokines with elevated concentrations in right eye were also raised in left eye, except for IL-2. Significant elevation was further shown for 6 cytokines in both right and left eye of aniridia patients compared with controls. These six were: IL-1 β , IL-9, IL-17A, eotaxin, FGF2, and MIP-1 α . No significant differences were found between right and left eye within the aniridia and patient group.

The level of IL-1RA was lower in aniridia in all test groups, but the differences were not statistically significant. However, the ratio between IL-1RA and IL-1 β was significantly lower in the aniridia group in both eyes and with both Schirmer and capillary test: in SOD 17,086 \pm 24,555 in aniridia versus 163,852 \pm 308,989 in controls ($P = 0.005$); in SOS 8890 \pm 20,092 versus 104,790 \pm 127,283 ($P = 0.001$); and in COS 749 \pm 1611 versus 2238 \pm 3085 ($P = 0.03$). The difference in the IL-1RA/IL-1 β ratio was not significant in COD (971 \pm 1297 versus 4902 \pm 5707, $P = 0.07$).

TABLE 3. Tear Cytokines in Left Eye With Significantly Different Concentrations in Aniridia and Control Group

Cytokine*	Aniridia	Control	P Value†
IL-1 β (S)	20.3 \pm 32.8	0.7 \pm 1.6	0.000004
IL-4 (S)	1.7 \pm 1.7	0.5 \pm 0.3	0.0002
IL-6 (S)	6.5 \pm 6.6	1.7 \pm 1.8	0.001
IL-8 (S)	109.0 \pm 180.7	36.2 \pm 63.4	0.002
IL-9 (S)	6.8 \pm 6.12	0.7 \pm 1.0	0.000008
IL-10 (S)	14.2 \pm 6.7	8.1 \pm 5.4	0.003
IL-12 p70 (S)	30.9 \pm 17.7	11.9 \pm 11.7	0.0003
IL-13 (S)	15.0 \pm 12.2	5.7 \pm 6.0	0.002
IL-17A (S)	18.6 \pm 23.5	0.6 \pm 2.6	0.00007
IL-17A (C)	93.5 \pm 103.9	1.5 \pm 5.3	0.001
Eotaxin (S)	15.5 \pm 13.4	4.9 \pm 5.4	0.001
FGF2 (S)	56.8 \pm 45.7	2.1 \pm 8.6	0.00005
FGF2 (C)	163.7 \pm 147.7	10.7 \pm 38.6	0.001
G-CSF (S)	40.0 \pm 30.9	18.6 \pm 13.6	0.002
IFN- γ (S)	44.8 \pm 43.9	16.9 \pm 12.6	0.002
MCP-1 (S)	58.1 \pm 85.7	26.3 \pm 38.0	0.003
MIP-1 α (S)	2.0 \pm 1.9	0.0 \pm 0.2	0.000002
MIP-1 β (S)	13.2 \pm 24.6	3.2 \pm 4.7	0.002
PDGF-BB (S)	18.9 \pm 13.5	4.6 \pm 4.8	0.00001

G-CSF, granulocyte colony-stimulating factor; MCP, monocyte chemoattractant protein; PDGF, platelet-derived growth factor.

* Mean \pm SD; Cytokines (pg/mL).

† Mann-Whitney *U* test and Holm-Bonferroni method.

Correlation Between Cytokine Levels and DED Findings in Aniridia Group

The five cytokines that were significantly elevated in both eyes and with both Schirmer and capillary test in at least one eye, were included in correlation analyses. These five cytokines were: IL-1 β , IL-9, IL-17A, FGF2, and MIP-1 α . Correlations were calculated between cytokine levels and clinical findings in the aniridia group (Fig.; Table 4).

Considering the relationship between tear production and cytokine concentrations, positive correlations were found between Schirmer test results in right eye and cytokines extracted from SOD for all five cytokines in the analysis (IL-1 β : $r = 0.622$, $P = 0.001$; IL-9: $r = 0.519$, $P = 0.006$; IL-17A: $r = 0.382$, $P = 0.049$; FGF2: $r = 0.423$, $P = 0.03$; MIP-1 α : $r = 0.588$, $P = 0.001$). Hence, increased Schirmer values correlated with raised cytokine levels. On the other hand, tear meniscus height correlated negatively with MIP-1 α in the left eye (SOS; $r = -0.450$, $P = 0.02$).

Negative correlations were found between fluorescein break-up time and the concentration of IL-17A ($r = -0.457$, $P = 0.03$) and FGF2 ($r = -0.598$, $P = 0.003$) in SOD, and between positive lipography and the level of IL-9 ($r = -0.400$, $P = 0.04$) and IL-17A ($r = -0.423$, $P = 0.03$) in SOS. Thus, longer tear break-up time, and visualization of the tear film by lipography were associated with lower concentrations of tear cytokines.

Positive correlations were observed between meiboscore in lower eyelid and all five cytokines in the analysis (for IL-1 β , IL-9, IL-17A, and FGF2 in more than one group; for MIP-1 α in COD). Loss of meibomian glands was therefore related to increasing levels of cytokines. Conjunctival alterations, in terms of hyperemia and papillae, were connected to elevated concentrations of IL-17A and FGF2 in SOS.

Correlation Between Cytokine Levels and Other Clinical Findings

The level of IL-17A correlated negatively with corneal esthesiometry values ($r = -0.441$, $P = 0.03$) in SOD (i.e.,

increased level of IL-17A was associated with lower corneal sensitivity). Presence of total iris hypoplasia correlated positively with IL-1 β in COS ($r = 0.477$, $P = 0.045$).

DISCUSSION

Our results demonstrate significantly higher concentrations of a number of inflammatory cytokines in tear fluid from aniridia patients than in healthy controls. Additionally, the level of certain cytokines correlates with clinical parameters commonly used in diagnostics of DED, including tests for MGD. The concentrations of 18 cytokines were significantly higher in aniridia than controls in at least one test subgroup (SOD, COD, SOS, and COS). None of the cytokines tested had significantly lower concentrations in the aniridia group. However, the ratio between the anti-inflammatory IL-1RA and the pro-inflammatory IL-1 β was significantly higher in controls. The levels of six cytokines were significantly elevated in both eyes in aniridia (IL-1 β , IL-9, IL-17A, eotaxin, FGF2, and MIP-1 α). Bilateral confirmation of these six cytokines makes it reasonable to consider them as particularly important among the tested proteins.

Several studies have successfully used multiplex bead analysis in examination of tear fluid.¹²⁻¹⁴ Smaller sample volumes are needed with this method than traditional procedure—ELISA—thus both eyes could be tested separately without need to pool samples.¹⁵ Furthermore, multiplex analysis has good correlation with ELISA test, rapid processing and high throughput, which allows quantification of multiple protein targets.¹⁵

A different number of cytokines with significantly higher concentrations was detected with Schirmer test and capillary test from the same eye, and in the right and left eyes. This might reflect variability in expression and severity of disease between the two eyes in a patient with aniridia, and the ability to detect these differences by Schirmer and capillary test. On the other hand, the Schirmer strip was always first inserted into right inferior fornix, and the capillary test started with right eye, which could have influenced the results. Moreover, the number of samples achieved was higher with Schirmer test than with capillary test, and higher in right eye than left eye. Cytokine levels in the Schirmer test groups correlated better with clinical parameters than those from capillary test groups. Our study therefore indicates that Schirmer test from one eye should be chosen when collecting tear samples for cytokine analyses. Exclusion of Schirmer tests with 5 mm wetting or less may have impacted our results by excluding participants with more severe DED.

Several cytokines have been identified in tear fluid from normal individuals.¹⁵ Both proinflammatory and anti-inflammatory cytokines are present in normal eyes without inflammation,¹⁶ and some of these are suggested to participate in the host defense system at the ocular surface.¹⁵ Elevated concentration of tear fluid cytokines has been shown in patients harboring systemic diseases which affect the ocular surface, such as graft-versus-host-disease,¹⁷ and in inflammatory eye diseases involving the ocular surface.¹⁸

Increased level of many inflammatory cytokines has been evident in patients with DED.^{6,12} The prevalence of DED in the aniridia is high,^{4,5} and correlates with severity of AAK.⁵ AAK could lead to corneal ulceration and inflammation,¹⁹ and be a sight threatening complication in aniridia.

Elevated concentrations of IL-1 β have been found in tear fluid from DED patients,^{6,14} and recognized as the earliest change in patients with DED.¹⁴ In our study, higher concentration of IL-1 β was associated with lower age in the aniridia group. This may reflect that increased level of IL-1 β is an initial

TABLE 4. Correlation Analysis Between Levels of Five Selected Tear Cytokines and Clinical Parameters in the Aniridia Group

Clinical Parameter	Test Group	Cytokine	Correlation Coefficient*	P Value*
Age	SOD	IL-1 β	-0.485	0.01
Tear production				
Tear meniscus height	SOS	MIP-1 α	-0.450	0.02
Schirmer test	SOD/SOS	IL-1 β	0.622/0.618	0.001/0.001
	SOD	IL-9	0.519	0.006
	SOD	IL-17A	0.382	0.049
	SOD	FGF2	0.423	0.03
	SOD	MIP-1 α	0.588	0.001
Phenol red test	SOS	FGF2	0.821	0.02
Tear film quality				
Break-up time	SOD	IL-17A	-0.457	0.03
	SOD	FGF2	-0.598	0.003
Lipography (positive)	SOS	IL-9	-0.400	0.04
	SOS	IL-17A	-0.423	0.03
Eyelid				
Telangiectasia eyelid	SOS	FGF2	0.522	0.006
Meiboscore	SOD/COD	IL-1 β	0.488/0.477	0.04/0.04
Lower eyelid	SOD/SOS	IL-9	0.488/0.516	0.02/0.01
	SOD/COD/SOS	IL-17A	0.470/0.457/0.460	0.03/0.049/0.03
	COD/SOS	FGF2	0.464/0.452	0.04/0.04
	COD	MIP-1 α	0.477	0.04
Conjunctiva				
Conjunctival hyperemia	COD	IL-1 β	0.427	0.047
	SOS	IL-17A	0.418	0.03
Conjunctival papillae	SOS	IL-17A	0.407	0.04
	SOS	FGF2	0.529	0.005
Cornea				
Corneal sensitivity	SOD	IL-17A	-0.441	0.03
Iris				
Iris hypoplasia	COS	IL-1 β	0.477	0.045

* Spearman's rank correlation.

finding in DED in aniridia. It is further suggested that IL-17A plays a role in the pathogenesis of DED.²⁰ The level of IL-17A in tears and its expression in conjunctiva also correlated well with parameters for DED. IL-1 β and IL-17A were significantly increased in both eyes in our study. Additionally, significant correlations were found between the level of several cytokines and parameters for DED, including tests for MGD. Interestingly, increasing Schirmer test values corresponded with higher concentration of a number of cytokines. This might reflect increased tear production as a marker for enhanced inflammation at the ocular surface in aniridia patients. Raised tear production is probably also a compensatory mechanism in MGD.²¹

In a study by Enriquez-de-Salamanca et al.,²² increased levels of inflammatory cytokines were found in patients with moderate forms of evaporative DED due to MGD. Moreover, correlations were demonstrated between cytokines and clinical parameters for DED. In aniridia, MGD has been identified as a possible factor in the development of DED in most patients.⁵ It is likely that MGD contributes to the tear cytokine profile demonstrated in aniridia patients. In our study, this argument is supported by moderate to strong correlations between elevated cytokine concentrations and increased atrophy of MGs in terms of meiboscore. Furthermore, positive lipography, indicating maintained tear film lipid layer, was associated with decreased level of IL-9 and IL-17A. Longer break-up time of the tear film, implying better function of the tear lipid layer, was associated with lower concentration of IL-17A and FGF2 and hence less inflammation. Additionally, the presence of eyelid and conjunctival pathologies correlated positively with the level of cytokines in certain subgroups.

Eyelid changes could potentially contribute to the development of MGD, or possibly be a consequence of the disease.²³

Clinically, corneal ulceration and inflammation are frequently observed in aniridia patients,¹⁹ and the presence of inflammatory cells in the corneal limbal region was demonstrated by laser scanning in vivo confocal microscopy.²⁴ Confocal microscopy also showed inflammatory cells in the central cornea despite transparency by slit-lamp examination.²⁵ Thus, it is likely that corneal processes contribute to inflammation at the ocular surface and increase the concentration of inflammatory substances in the tear film. Correlation between stage of AAK and cytokine level was not shown in our study, possibly because the number of participants was not large enough for subgroup analysis. In future studies, cytokine levels should be analyzed in each group of AAK if enough patients exist.

Proinflammatory properties characterize all six cytokines that were significantly elevated in both eyes (IL-1 β , IL-9, IL-17A, eotaxin, FGF2, and MIP-1 α). The expression of IL-1 β is increased in the tissue covering cornea (pannus) in limbal stem cell deficiency.²⁶ Furthermore, highly elevated expression of IL-9 has been found in conjunctival cells of patients with DED connected to graft versus host disease.²⁷ Th17 cells mediate ocular surface autoimmunity through IL-17A.²⁸ Eotaxin secreted in tears is important in the pathogenesis of seasonal allergic conjunctivitis.²⁹ Moreover, increased expression of eotaxin was shown in tears and conjunctival epithelial cells of patients with vernal keratoconjunctivitis.³⁰ Upregulation of FGF2 in tear fluid has been found in cases of chronic Stevens-Johnson syndrome.³¹ Furthermore, an elevated level of MIP-1 α /CCL3 was demonstrated together with increasing degree of




FIGURE. Scatter plot of correlation between clinical parameters and concentration of various inflammatory tear cytokines collected with Schirmer test in right eye: (A) correlation between Schirmer test results (mm) and concentration of IL-1 β (pg/mL); (B) between Schirmer test results and MIP-1 α ; (C) tear film break-up time (s) and FGF2; (D) tear film break-up time and IL-17A; (E) meiboscore and IL-9; (F) meiboscore and IL-1 β . *R* and *P* values calculated with Spearman's rank correlation.

neutrophilic cells in a corneal model.³² MIP-1 α /CCL3 represents an important signal for mast cell degranulation in the conjunctiva and hence for acute-phase disease.³³

The proinflammatory IL-1 β is an agonist and the anti-inflammatory IL-1RA an antagonist to the same receptors, and the balance between IL1 and IL-1RA impacts the development of inflammatory diseases.³⁴ In our study, the ratio between IL-1RA and IL-1 β was significantly reduced in aniridia. This finding indicates an imbalance between pro- and anti-inflammatory cytokines in aniridia patients, and suggests that a restoration of this cytokine balance (which exists in tears from healthy subjects) could be a future therapeutic goal.

Research points to inflammatory events at the ocular surface as a core mechanism in the development of DED.^{7,35} AAK probably enhances these events and serves as a possible trigger for DED in aniridia patients. Moreover, DED potentially leads to ocular surface epithelial disease and altered corneal epithelial barrier function.⁷ Accordingly, AAK and DED may interact, progressively breaking down the normal corneal anatomy and reducing the patient's vision.

In conclusion, our study demonstrates significantly higher levels of a number of inflammatory cytokines in tear fluid from aniridia patients than in control individuals. Moderate correlations were found between cytokine concentrations and parameters for DED, especially MGD. Increased inflammation of the ocular surface may in part explain the high prevalence of DED in aniridia. In turn, MGD and hence DED possibly contribute to elevated cytokine levels in the tear fluid. As inflammation may lead to deterioration of AAK and consequently the patient's vision, attention should be directed toward possible treatment options targeting these disease pathways.

Acknowledgments

The authors thank Geir A. Qvale, Department of Ophthalmology, Oslo University Hospital, Norway, for graphical editing.

Presented at the annual meeting for the Association for Research in Vision and Ophthalmology, Baltimore, Maryland, United States, May 2017, and at the annual meeting for the Norwegian Ophthalmological Society, Oslo, Norway, November 2017.

Supported in part by the patient organization Aniridia Norway (Oslo, Norway), Dr. Jon S. Larsen's Foundation (Tønsberg, Norway); Inger Holm's Memorial Foundation (Oslo, Norway); the Norwegian Association of the Blind and Partially Sighted (Oslo, Norway); the Norwegian Ophthalmological Society (Oslo, Norway); and the Department of Ophthalmology and Department of Medical Biochemistry at Oslo University Hospital (Oslo, Norway). The authors alone are responsible for the content and writing of the paper.

Disclosure: **E.C.S. Landsend**, None; **Ø.A. Utheim**, None; **H.R. Pedersen**, None; **H.C.D. Aass**, None; **N. Lagali**, None; **D.A. Dartt**, None; **R.C. Baraas**, None; **T.P. Utheim**, None

References

- Eden U, Iggman D, Riise R, Tornqvist K. Epidemiology of aniridia in Sweden and Norway. *Acta Ophthalmol.* 2008;86:727-729.
- Lee H, Khan R, O'Keefe M. Aniridia: current pathology and management. *Acta Ophthalmol.* 2008;86:708-715.
- Prosser J, van Heyningen V. PAX6 mutations reviewed. *Hum Mutat.* 1998;11:93-108.
- Shiple D, Finklea B, Lauderdale JD, Netland PA. Keratopathy, cataract, and dry eye in a survey of aniridia subjects. *Clin Ophthalmol.* 2015;9:291-295.
- Jastancic S, Al-Rajhi AA. Association of aniridia and dry eyes. *Ophthalmology.* 2005;112:1535-1540.
- Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. *Cornea.* 2009;28:1023-1027.
- Stern ME, Pflugfelder SC. Inflammation in dry eye. *Ocul Surf.* 2004;2:124-130.
- Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. *Cornea.* 2003;22:640-650.
- Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. *Invest Ophthalmol Vis Sci.* 2011;52:2006-2049.
- Mackman G, Brightbill FS, Optiz JM. Corneal changes in aniridia. *Am J Ophthalmol.* 1979;87:497-502.
- Chylack LT Jr, Wolfe JK, Singer DM, et al. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. *Arch Ophthalmol.* 1993;111:831-836.
- Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. Tear cytokine profiles in dysfunctional tear syndrome. *Am J Ophthalmol.* 2009;147:198-205.e191.
- Hagan S, Tomlinson A. Tear fluid biomarker profiling: a review of multiplex bead analysis. *Ocul Surf.* 2013;11:219-235.
- Na KS, Mok JW, Kim JY, Rho CR, Joo CK. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. *Invest Ophthalmol Vis Sci.* 2012;53:5443-5450.
- Sack RA, Conradi L, Krumholz D, Beaton A, Sathe S, Morris C. Membrane array characterization of 80 chemokines, cytokines, and growth factors in open- and closed-eye tears: angiogenin and other defense system constituents. *Invest Ophthalmol Vis Sci.* 2005;46:1228-1238.
- Sonoda S, Uchino E, Nakao K, Sakamoto T. Inflammatory cytokine of basal and reflex tears analyzed by multicytokine assay. *Br J Ophthalmol.* 2006;90:120-122.
- Riemens A, Stoyanova E, Rothova A, Kuiper J. Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. *Mol Vis.* 2012;18:797-802.
- Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. *Clin Exp Allergy.* 2000;30:103-109.
- Lopez-Garcia JS, Garcia-Lozano I, Rivas L, Martinez-Garchitorenna J. [Congenital aniridia keratopathy treatment]. *Arch Soc Esp Ophthalmol.* 2006;81:435-444.
- Liu R, Gao C, Chen H, Li Y, Jin Y, Qi H. Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease. *PLoS One.* 2017;12:e0173301.
- Arita R, Morishige N, Koh S, et al. Increased tear fluid production as a compensatory response to meibomian gland loss: a multicenter cross-sectional study. *Ophthalmology.* 2015;122:925-933.
- Enriquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. *Mol Vis.* 2010;16:862-873.
- Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. *Invest Ophthalmol Vis Sci.* 2011;52:1922-1929.
- Lagali N, Eden U, Utheim TP, et al. In vivo morphology of the limbal palisades of Vogt correlates with progressive stem cell deficiency in aniridia-related keratopathy. *Invest Ophthalmol Vis Sci.* 2013;54:5333-5342.
- Lagali N, Wowra B, Dobrowolski D, Utheim TP, Fagerholm P, Wylegala E. Stage-related central corneal epithelial transfor-

- mation in congenital aniridia-associated keratopathy. *Ocul Surf.* 2018;16:163-172.
26. Pauklin M, Steuhl KP, Meller D. Characterization of the corneal surface in limbal stem cell deficiency and after transplantation of cultivated limbal epithelium. *Ophthalmology.* 2009;116:1048-1056.
 27. Cocho L, Fernandez I, Calonge M, et al. Gene expression-based predictive models of graft versus host disease-associated dry eye. *Invest Ophthalmol Vis Sci.* 2015;56:4570-4581.
 28. Chen Y, Chauhan SK, Shao C, Omoto M, Inomata T, Dana R. IFN-gamma-expressing Th17 cells are required for development of severe ocular surface autoimmunity. *J Immunol.* 2017;199:1163-1169.
 29. Eperon S, Berquiga M, Ballabeni P, Guex-Crosier C, Guex-Crosier Y. Total IgE and eotaxin (CCL11) contents in tears of patients suffering from seasonal allergic conjunctivitis. *Graefes Arch Clin Exp Ophthalmol.* 2014;252:1359-1367.
 30. Shoji J, Inada N, Sawa M. Evaluation of eotaxin-1, -2, and -3 protein production and messenger RNA expression in patients with vernal keratoconjunctivitis. *Jpn J Ophthalmol.* 2009;53:92-99.
 31. Gurumurthy S, Iyer G, Srinivasan B, Agarwal S, Angayarkanni N. Ocular surface cytokine profile in chronic Stevens-Johnson syndrome and its response to mucous membrane grafting for lid margin keratinisation. *Br J Ophthalmol.* 2018;102:169-176.
 32. Gong Y, Koh DR. Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model. *Cell Tissue Res.* 2010;339:437-448.
 33. Miyazaki D, Nakamura T, Toda M, Cheung-Chau KW, Richardson RM, Ono SJ. Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. *J Clin Invest.* 2005;115:434-442.
 34. Arend WP. The balance between IL-1 and IL-1Ra in disease. *Cytokine Growth Factor Rev.* 2002;13:323-340.
 35. Research in dry eye: report of the research subcommittee of the International Dry Eye WorkShop. *Ocul Surf.* 2007;5:179-193.